My Cart [ 0 ]
Home > Antibodies > A-Z Primary Antibodies > Rituximab Biosimilar, CD20 Monoclonal Antibody

Rituximab Biosimilar, CD20 Monoclonal Antibody

Anti-CD20 Chimeric Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C010P Rituximab Biosimilar, CD20 Monoclonal Antibody 10 mg 500.00
C010P Rituximab Biosimilar, CD20 Monoclonal Antibody 50 mg 750.00
C010P Rituximab Biosimilar, CD20 Monoclonal Antibody 100 mg 1000.00
C010P Rituximab Biosimilar, CD20 Monoclonal Antibody 1 g 3000.00
Description

C010P: Rituximab Biosimilar, CD20 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The monoclonal antibody rituximab biosimilar was produced in the Rituximab biosimilar CHO stable cell line.
Specificity/Sensitivity: The monoclonal antibody rituximab biosimilar specifically binds to the human TNF alpha.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by rituximab.
Form of Antibody: 0.2 uM filtered solution, pH 6.5, no stabilizers or preservatives.
Endotoxin: < 0.1 EU per 1 ug of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The monoclonal antibody rituximab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues.

Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.

Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)

Related Links

See our Privacy Policy